Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Progression-free survival: meaningful or simply measurable?

Booth CM, Eisenhauer EA.

J Clin Oncol. 2012 Apr 1;30(10):1030-3. doi: 10.1200/JCO.2011.38.7571. No abstract available.

PMID:
22370321
2.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials..

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Review.

PMID:
18477802
3.

[Health related quality of life and endpoints in oncology].

Bonnetain F.

Cancer Radiother. 2010 Oct;14(6-7):515-8. doi: 10.1016/j.canrad.2010.06.001. Review. French.

PMID:
20674446
4.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
5.

Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer.

Kitchener HC.

Cancer Treat Rev. 2005 Jun;31(4):323-7. Review. No abstract available.

PMID:
15905036
6.

Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.

Sridhara R, Mandrekar SJ, Dodd LE.

Clin Cancer Res. 2013 May 15;19(10):2613-20. doi: 10.1158/1078-0432.CCR-12-2938. Review.

7.

Systemic therapy for metastatic urothelial carcinoma.

Lin CC, Hsu CH, Pu YS, Vogelzang NJ.

BJU Int. 2008 Apr;101(7):795-803. Review. No abstract available.

8.

Overview: progression-free survival as an endpoint in clinical trials with solid tumors.

Korn RL, Crowley JJ.

Clin Cancer Res. 2013 May 15;19(10):2607-12. doi: 10.1158/1078-0432.CCR-12-2934. Review.

9.

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Wilkerson J, Fojo T.

Cancer J. 2009 Sep-Oct;15(5):379-85. doi: 10.1097/PPO.0b013e3181bef8cd. Review.

PMID:
19826357
10.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
11.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
12.

[Adjuvant therapy for colon cancer].

Moiseenko VM, Orlova RV.

Vopr Onkol. 1998;44(6):741-5. Review. Russian. No abstract available.

PMID:
10087982
13.

Assessment of quality of life during chemotherapy.

Gunnars B, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):175-84. Review.

PMID:
11441930
14.
15.

Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials.

de Kort SJ, Willemse PH, Habraken JM, de Haes HC, Willems DL, Richel DJ.

Eur J Cancer. 2006 May;42(7):835-45. Review.

PMID:
16481158
16.

The evidence-based use of induction chemotherapy in breast cancer.

Stebbing J J, Gaya A.

Breast Cancer. 2001;8(1):23-37. Review.

PMID:
11180763

Supplemental Content

Support Center